ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 903,29
0,23%
DAX
17 932,17
-1,10%
Brent Oil
83,695
0,19%
Bitcoin
57 359,12
-1,51%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Poseida Therapeutics Inc (PSTX)

  7. Poseida Therapeutics Inc (PSTX) Actualités

PSTX Poseida Therapeutics Inc

2,74
0,32 (13,22%)
02 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Poseida Therapeutics Inc PSTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,32 13,22% 2,74 00:31:32
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,69 2,685 3,00 2,77 2,42
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/5/202403:30PRNUSAstellas and Poseida Therapeutics Enter Into Research..
01/5/202421:25APSBiotech Soars on Research Collaboration And License..
01/5/202415:00PRNUSAstellas and Poseida Therapeutics Enter Into Research..
18/4/202414:00PRNUSPoseida Therapeutics Announces Strong Lineup of..
17/4/202415:00PRNUSPoseida Therapeutics Hosts Gene Therapy R&D Day Highlighting..
08/4/202418:00PRNUSPoseida Therapeutics Presents New Phase 1 Data at AACR 2024..
01/4/202422:05PRNUSPoseida Therapeutics Announces Inducement Grant Under Nasdaq..
25/3/202421:05PRNUSPoseida Therapeutics Appoints Syed Rizvi, M.D., as Chief..
19/3/202421:05PRNUSPoseida Therapeutics to Present at H.C. Wainwright 2nd..
13/3/202421:05PRNUSPoseida Therapeutics Announces FDA Orphan Drug Designation..
07/3/202422:07PRNUSPoseida Therapeutics Provides Updates and Financial Results..
07/3/202422:05EDGAR2Form 8-K - Current report
04/3/202423:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202423:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:05PRNUSPoseida Therapeutics Announces Inducement Grant Under Nasdaq..
08/2/202422:10EDGAR2Form S-8 - Securities to be offered to employees in employee..
04/1/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:01EDGAR2Form 8-K - Current report
04/1/202414:00PRNUSPoseida Therapeutics Highlights Recent Progress, Strategic..
11/12/202316:31DJNPoseida Therapeutics Shares Climb on Positive Data for Blood..
11/12/202312:06EDGAR2Form 8-K - Current report
10/12/202318:00PRNUSPoseida Therapeutics Presents Positive Early Results from..
09/11/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:05EDGAR2Form 8-K - Current report
09/11/202322:05PRNUSPoseida Therapeutics Provides Updates and Financial Results..
07/11/202314:00PRNUSPoseida Therapeutics to Present at Two Upcoming Investor..
02/11/202314:01PRNUSPoseida Therapeutics to Present at the 65th ASH Annual..
09/10/202322:30PRNUSPoseida Therapeutics Announces Leadership Transition
05/9/202314:00PRNUSPoseida Therapeutics to Present at Two Upcoming Investor..
14/8/202322:41EDGAR2Form SC 13D - General statement of acquisition of beneficial..
11/8/202322:48EDGAR2Form D - Notice of Exempt Offering of Securities
08/8/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:06EDGAR2Form 8-K - Current report
08/8/202322:05PRNUSPoseida Therapeutics Provides Financial Results for the..
07/8/202316:41DJNPoseida Therapeutics Shares Leap on Astellas Investments
07/8/202315:58DJNPoseida Therapeutics in $50 Million Investment Deal With..
07/8/202315:01EDGAR2Form 8-K - Current report
07/8/202315:01PRNUSPoseida Therapeutics Announces Strategic Investment by..
07/8/202315:00PRNUSAstellas and Poseida Therapeutics Announce Strategic..
05/7/202314:00PRNUSPoseida Therapeutics Announces FDA Clearance of..
26/6/202314:00PRNUSPoseida Therapeutics to Join Russell 3000® and Russell 2000®..
01/6/202314:00PRNUSPoseida Therapeutics Announces Virtual 2023 Annual Meeting..
23/5/202314:00PRNUSPoseida Therapeutics to Present at Stifel 2023 Tailoring..
22/5/202314:00PRNUSPoseida Therapeutics to Present at 31st Congress of the..
18/5/202314:00PRNUSPoseida Therapeutics Presents Encouraging Preclinical Data..
09/5/202322:05PRNUSPoseida Therapeutics Provides Updates and Financial Results..

Dernières Valeurs Consultées

NASDAQ
PSTX
Poseida Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés